Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
企業コードELUT
会社名Elutia Inc
上場日Oct 08, 2020
最高経営責任者「CEO」Mills (C. Randal)
従業員数51
証券種類Ordinary Share
決算期末Oct 08
本社所在地12510 Prosperity Drive
都市SILVER SPRING
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号20904
電話番号12402471143
ウェブサイトhttps://elutia.com/
企業コードELUT
上場日Oct 08, 2020
最高経営責任者「CEO」Mills (C. Randal)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし